Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

fda2outsideweb

AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction

May 6, 2020 Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …
News
partnership

Portola Pharmaceuticals to merge with Alexion in $1.41bn cash deal

May 6, 2020 Research and Development, Sales and Marketing Alexion, Portola Pharmaceuticals, pharma

Alexion has announced it is to acquire Boston-based blood disorder specialist Portola Pharmaceuticals in a transaction to the value of …
News
coroanrvisu_cdc

Pharmafile.com’s weekly COVID-19 news round-up

May 6, 2020 Research and Development COVID-19, coronavirus

Vaccines and treatments for COVID-19 continue to dominate the news, as two studies reveal “positive” data for Gilead’s remdesivir in …
News
trumpppppp

Ousted chief of BARDA says Trump administration ignored COVID-19 warnings

May 6, 2020 Research and Development BARDA, COVID-19, chloroquine, coronavirus, hydroxychloroquine

Ousted Director of the Biomedical Advanced Research and Development Authority (BARDA), Dr Rick Bright, alleges the Trump administration ignored warnings …
News
s300_yellow-card-govuk960

MHRA launches new pharmacovigilance reporting platform for COVID-19 treatments

May 5, 2020 Manufacturing and Production, Research and Development COVID-19, MHRA, UK, coronavirus, pharma

A new online reporting site has been launched by the Medicines and Healthcare products Regulatory Agency’s (MHRA) to track potential …
News
shutter

Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer

May 5, 2020 Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …
News
kim_stratton_orphazyme

Working Life Interview: Kim Stratton, CEO, Orphazyme

May 4, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Interview, Orphazyme, Working Life

“Every professional faces challenges. As a woman in industry, particularly in leadership, it adds another dimension to those challenges in …
Feature
top_10_image_2_1

Top Ten most popular articles on Pharmafile.com this week

May 1, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Gilead, UK, coronaviurs

The search for a COVID-19 treatment has ramped up this week, with two new studies detailing the efficacy of Gilead’s …
News
512px-oxford_university_colleges-all_souls1

AstraZeneca joins forces with University of Oxford to develop and manufacture potential coronavirus vaccine

April 30, 2020 Manufacturing and Production, Research and Development AstraZeneca, COVID-19, University of Oxford, coronavirus, pharma

A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with …
News
gilead-speeds-manufacture-of-experimental-covid-19-drug-biospace-4-5-20-495x350

Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patients

April 30, 2020 Research and Development COVID-19, Gilead, coronavirus, remdesivir

The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the …
News
korean_1

Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trials

April 29, 2020 Research and Development chloroquine, hydroxychloroquine

The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider …
News
shutterstock

Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer

April 29, 2020 Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer

A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
News
aussss

Australia calls for investigation into China’s coronavirus response

April 29, 2020 Research and Development Australia, COVID-19, China, coronavirus

Scott Morrison, the Australian Prime Minister, has called for an investigation into the origins of the COVID-19 coronavirus, as Australia …
News
covid_cell

Pharmafile.com’s weekly COVID-19 news round-up

April 29, 2020 Research and Development BARDA, COVID-19, coronavirus, hydroxychloroquine

Hydroxychloroquine continues to feature in coronavirus news. Rick Bright, the Director of BARDA, alleges he was pushed out of his …
News
novartis_outside_1

EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis

April 29, 2020 Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026